Assistant Professor, Radiation Oncology, University of Michigan Medical School
Radiation Oncology
Dr. Felix Feng, MD
|
|
Give Review
Felix Feng works in the field of Radiation Oncology. He went to Washington University School of Medicine in St. Louis. He received awards:"CMS Meaningful Use Stage 1 Certification". Felix Feng, MD is a published MD. He published 90 publications, including: 'Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.' He accepts all Medicare patients.
Publications
- Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.
- Prognostic value of percent Gleason grade 4 at prostate biopsy on predicting prostatectomy pathology and recurrence.
- Clinicopathologic characteristics of anterior prostate cancer (APC), including correlation with previous biopsy pathology.
- Definition and Validation of "Favorable High-Risk Prostate Cancer": Implications for Personalizing Treatment of Radiation-Managed Patients.
- Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
- Association between very small tumor size and increased cancer-specific mortality following radical prostatectomy in node-positive prostate cancer.
- Integrative molecular profiling of routine clinical prostate cancer specimens.
- Targeting the MLL complex in castration-resistant prostate cancer.
- Consequence of the tumor-associated conversion to cyclin D1b.
- The landscape of long noncoding RNAs in the human transcriptome.
- A Novel RNA In Situ Hybridization Assay for the Long Noncoding RNA SChLAP1 Predicts Poor Clinical Outcome After Radical Prostatectomy in Clinically Localized Prostate ...
- RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
- Tumor evolution and progression in multifocal and paired non-invasive/invasive urothelial carcinoma.
- The Long Non-Coding RNA PCAT-1 Promotes Prostate Cancer Cell Proliferation through cMyc.
- High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men...
- A TISSUE BIOMARKER BASED MODEL THAT IDENTIFIES PATIENTS WITH A HIGH RISK OF DISTANT METASTASIS AND DIFFERENTIAL SURVIVAL BY LENGTH OF ANDROGEN DEPRIVATION THERAPY IN R...
- A pilot study of diffusion-weighted MRI in patients undergoing neoadjuvant chemoradiation for pancreatic cancer.
- MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?
- Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy.
- The lncRNA PCAT29 Inhibits Oncogenic Phenotypes in Prostate Cancer.
- Understanding the Relationship Between Tumor Size, Gland Size, and Disease Aggressiveness in Men With Prostate Cancer.
- Molecular Pathways: Targeting ETS Gene Fusions in Cancer.
- A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer(1,2.)
- Patient-Reported Voice and Speech Outcomes After Whole-Neck Intensity Modulated Radiation Therapy and Chemotherapy for Oropharyngeal Cancer: Prospective Longitudinal S...
- Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
- The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.
- Nonendemic HPV-Positive Nasopharyngeal Carcinoma: Association With Poor Prognosis.
- Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer.
- PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer.
- The central role of EED in the orchestration of polycomb group complexes.
- Limitations of the Cancer of the Prostate Risk Assessment (CAPRA) Prognostic Tool for Prediction of Metastases and Prostate Cancer-specific Mortality in Patients Treat...
- Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.
- A Hormone-DNA Repair Circuit Governs the Response to Genotoxic Insult.
- A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy.
- Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radia...
- Targeted Radiosensitization of ETS Fusion-Positive Prostate Cancer through PARP1 Inhibition.
- The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.
- Time to Nadir PSA: Of Popes and PSA-The Immortality Bias.
- Characterization of changes in total body composition for head and neck cancer patients undergoing chemoradiotherapy using dual-energy X-ray absorptiometry (DEXA).
- Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy f...
- Salvage Radiation Therapy Improves Metastasis-free Survival for Clinically Aggressive and Indolent Prostate Cancer Recurrences After Radical Prostatectomy.
- Aspiration pneumonia after chemo-intensity-modulated radiation therapy of oropharyngeal carcinoma and its clinical and dysphagia-related predictors.
- Interval to Biochemical Failure Predicts Clinical Outcomes in Patients With High-Risk Prostate Cancer Treated by Combined-Modality Radiation Therapy.
- Physiological imaging-defined, response-driven subvolumes of a tumor.
- The Interval to Biochemical Failure Is Prognostic for Metastasis, Prostate Cancer-Specific Mortality, and Overall Mortality After Salvage Radiation Therapy for Prostat...
- Weekly chemotherapy with radiation versus high-dose cisplatin with radiation as organ preservation for patients with HPV positive and HPV negative locally advanced squ...
- Identification of Targetable FGFR Gene Fusions in Diverse Cancers.
- Toxicities Affecting Quality of Life After Chemo-IMRT of Oropharyngeal Cancer: Prospective Study of Patient-Reported, Observer-Rated, and Objective Outcomes.
- Recurrent Rearrangements in Prostate Cancer: Causes and Therapeutic Potential.
- Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation fo...
- Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
- Dual Roles of PARP-1 Promote Cancer Growth and Progression.
- Urethral cancer.
- Age and Comorbid Illness Are Associated With Late Rectal Toxicity Following Dose-Escalated Radiation Therapy for Prostate Cancer.
- General commentary to the "management of biochemical recurrence after primary localized therapy for prostate cancer" by darwish o. M. And raj g. V.
- The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated exter...
- Lhermitte Sign After Chemo-IMRT of Head-and-Neck Cancer: Incidence, Doses, and Potential Mechanisms.
- WE-C-BRA-05: Physiological Imaging-Defined Response-Driven Subvolumes of a Tumor.
- Radiation Therapy with Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer.
- Percentage of Cancer Volume in Biopsy Cores is Prognostic for Prostate Cancer Death and Overall Survival in Patients Treated with Dose-Escalated External Beam Radiothe...
- Reducing Xerostomia After Chemo-IMRT for Head-and-Neck Cancer: Beyond Sparing the Parotid Glands.
- Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer.
- Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.
- Role of radiotherapy in the management of desmoid tumors.
- The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of ...
- Continued Benefit to Androgen Deprivation Therapy for Prostate Cancer Patients Treated with Dose-Escalated Radiation Therapy Across Multiple Definitions of High-Risk D...
- Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
- Chemo-IMRT of Oropharyngeal Cancer Aiming to Reduce Dysphagia: Swallowing Organs Late Complication Probabilities and Dosimetric Correlates.
- Gleason Pattern 5 is the Greatest Risk Factor for Clinical Failure and Death from Prostate Cancer after Dose-Escalated Radiation Therapy and Hormonal Ablation.
- Therapeutic targeting of SPINK1-positive prostate cancer.
- The Percent of Positive Biopsy Cores Improves Prediction of Prostate Cancer-Specific Death in Patients Treated With Dose-Escalated Radiotherapy.
- Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.
- Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
- HPV-positive/p16-positive/EBV-negative nasopharyngeal carcinoma in white North Americans.
- Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence.
- Sonography of wrist ganglion cysts: variable and noncystic appearances.
- Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation.
- Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
- Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
- Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences.
- Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.
- Chloroquine treatment increases detection of 5-fluorouracil-induced apoptosis index in vivo.
- Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
- A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy...
- Diffusion abnormality index: a new imaging biomarker for early assessment of tumor response to therapy.
- Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death followi...
- A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy.
- Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
- Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.
Schools
Washington Center School of Medicine
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Michigan Hospitals and Health Centers -
St Joseph Mercy Livingston Hospital -
Washington University School of Medicine in St. Louis
Hospital
-
University of Michigan Hospitals and Health Centers
Drug Facts
| NPI NUMBER | 1497874028 | |
| NPPES Provider LastName | FENG | |
| NPPES Provider FirstName | FELIX | |
| NPPES Provider ZIPCode | 481095010 | |
| NPPES Provider State | MI | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 38.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497874028 |
| Last Name Of The Provider | FENG |
| First Name Of The Provider | FELIX |
| View All |
Similar Doctors
|
|
Dr. Dean A. Shumway, MD |
|
|
Dr. Shruti Jolly, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel A. Hamstra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Annette E. Kretzler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle C. Cuneo, MD |
|
|
Dr. Iris Gluck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christina H. Chapman, MD |
|
|
Dr. Jennifer L. Webb, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica Zhou, MD |
|
|
Dr. Jae Y. Lee, MD |
|
|
Dr. Matthew H. Stenmark, MD
This Doctor is OpenDoctor Recommended.
|